Its injected once weekly and is expected to be submitted to the FDA for approval in 2026
GLP-1 drugs are currently in trials for several indications, including Phase 3 studies for non-alcoholic steatohepatitis (NASH)
Significant main effects of treatment group (prior to BenjaminiHochberg correction since none were significant after correction, although the necessity of correction for multiple comparisons in exploratory analyses remains unresolved 49 ) were observed for the unclassified group and ten classified genera, namely, Acetatifactor , Akkermansia , Erysipelatoclostridium , [ Eubacterium ] coprostanoligenes group , Family XIII UCG-001 , Lactobacillus , Parasutterella , Ruminiclostridium 6 , Ruminococcaceae UCG-004 , and Ruminococcaceae UCG-009
First, it can improve access to medication
Murati, McGrew and Zoph are the latest dominoes to fall
Oral GLP-1 drugs are typically taken once a day, with some patients noticing results within a few weeks of starting the medication